Literature DB >> 8370621

Invasive squamous-cell cervical carcinoma and combined oral contraceptives: results from a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.

.   

Abstract

Data from a hospital-based case-control study collected in 11 participating centers in 9 countries were analyzed to determine whether use of combined oral contraceptives alters risk of invasive squamous-cell cervical cancer. Information on prior use of oral contraceptives, screening for cervical cancer, and suspected risk factors for this disease were ascertained from interviews of 2361 cases and 13,644 controls. A history of smoking and anal and genital warts was obtained, and blood specimens were collected for measurement of antibodies against herpes simplex and cytomegaloviruses, from selected sub-sets of these women, as was a sexual history from interviews of husbands. The relative risk of invasive squamous-cell cervical carcinoma was estimated to be 1.31, with a 95% confidence interval that excluded one, in women who ever used combined oral contraceptives. Risk of this disease increased significantly with duration of use after 4 to 5 years from first exposure, and declined with the passage of time after cessation of use to that of non-users in about 8 years. No sources of bias or confounding were identified that offered plausible explanations for these findings. The strength of these results, and their consistency with those from other studies, suggest that a causal relationship may exist between use of combined oral contraceptives and squamous-cell cervical carcinoma. Women who have used these products for 4 or more years, and who most recently used them within the past 8 years, should receive high priority for cervical cytologic screening.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370621     DOI: 10.1002/ijc.2910550211

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Systematic literature reviews and meta-analyses: part 6 of a series on evaluation of scientific publications.

Authors:  Meike Ressing; Maria Blettner; Stefanie J Klug
Journal:  Dtsch Arztebl Int       Date:  2009-07-03       Impact factor: 5.594

2.  Human papillomavirus E7 oncoprotein dysregulates steroid receptor coactivator 1 localization and function.

Authors:  Amy Baldwin; Kyung-Won Huh; Karl Münger
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 3.  Current status of fertility control methods in India.

Authors:  R S Sharma; M Rajalakshmi; R S Sharma; D A Jeyaraj
Journal:  J Biosci       Date:  2001-11       Impact factor: 1.826

4.  Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model.

Authors:  Jiafen Hu; Sarah A Brendle; Jingwei J Li; Vonn Walter; Nancy M Cladel; Timothy Cooper; Debra A Shearer; Karla K Balogh; Neil D Christensen
Journal:  Viruses       Date:  2022-05-06       Impact factor: 5.818

5.  The upstream regulatory region of human papillomavirus type 31 is insensitive to glucocorticoid induction.

Authors:  Jennifer L Bromberg-White; Craig Meyers
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  Does oral contraceptive pill increase the risk of abnormal Pap smear?

Authors:  Fariba Binesh; Ali Akhavan; Azar Pirdehghan; Mahnoosh Davoodi
Journal:  Iran J Reprod Med       Date:  2013-09

7.  Risk factors associated with precancerous cervical lesion among women screened at Marie Stops Ethiopia, Adama town, Ethiopia 2017: a case control study.

Authors:  Roza Teshome Kassa
Journal:  BMC Res Notes       Date:  2018-02-20

8.  Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National Case-Control Study of Cervical Cancer.

Authors:  J Green; A Berrington de Gonzalez; S Sweetland; V Beral; C Chilvers; B Crossley; J Deacon; C Hermon; P Jha; D Mant; J Peto; M Pike; M P Vessey
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.